Corcept exec sells 58K shares after option exercise
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
CORCEPT THERAPEUTICS INC (CORT) reported that President, Oncology Roberto Wandenkolk Vieira exercised stock options for 58,333 shares of common stock at $21.63 per share on September 2, 2026, then sold 58,333 shares in multiple open-market transactions and had 102 shares withheld to satisfy tax obligations. These sales were made under a Rule 10b5-1 trading plan adopted on June 17, 2026. On September 1, 2026 he also acquired 138 shares through a purchase plan and 138 restricted shares that vest after one year.
Insider Trade Summary 10b5-1
Exercise and Sale: 58,333 shares ($5.20M approx. pre-tax spread)
Exercise and Sale
12 txns
Insider
Vieira Roberto Wandenkolk
Role
President, Oncology
Sold
58,333 shs ($6.46M)
Approx. gross sale proceeds
$6.46M
Approx. exercise cost
$1.26M
Approx. pre-tax spread
$5.20M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock option (right to buy) F16 | 58,333 | $0.00 | $0.00 |
| Tax Withholding | Common Stock F5, F6, F7 | 102 | $113.38 | $12K |
| Exercise | Common Stock F7 | 58,333 | $21.63 | $1.26M |
| Sale | Common Stock F8, F9, F7 | 23,600 | $109.3506 | $2.58M |
| Sale | Common Stock F8, F10, F7 | 23,770 | $110.7004 | $2.63M |
| Sale | Common Stock F8, F11, F7 | 1,537 | $111.3733 | $171K |
| Sale | Common Stock F8, F12, F7 | 974 | $112.3966 | $109K |
| Sale | Common Stock F8, F13, F7 | 1,606 | $113.7187 | $183K |
| Sale | Common Stock F8, F14, F7 | 5,621 | $114.5779 | $644K |
| Sale | Common Stock F8, F15, F7 | 1,225 | $115.4395 | $141K |
| Grant/Award | Common Stock F1, F2, F3 | 138 | $113.38 | $16K |
| Grant/Award | Common Stock F4, F3 | 138 | $0.00 | $0.00 |
Holdings After Transaction:
Stock option (right to buy) — 141,667 contracts (Direct);
Common Stock — 4,242 shares (Direct)
Footnotes (16)
- F1. The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.
- F2. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
- F3. Includes 199 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
- F4. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
- F5. These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
- F6. The closing price on September 1, 2026 was used to calculate the withholding obligation.
- F7. Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
- F8. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the reporting person being appointed an officer of the Issuer, which was in effect at the time of this transaction.
- F9. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $108.97 to $109.83 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F10. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $110.06 to $111.03 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F11. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $111.06 to $111.945 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F12. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.08 to $113.03 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F13. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.11 to $114.09 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F14. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.24 to $115.195 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F15. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.255 to $115.57 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F16. Shares subject to the stock option vested and became exercisable with respect to 25% of the shares underlying the option on January 29, 2025 with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on January 29, 2028, subject to the Reporting Person's continued service.
Key Figures
Options exercised: 58,333 shares
Option exercise price: $21.63 per share
Shares sold: 58,333 shares
+5 more
8 metrics
Options exercised
58,333 shares
Stock options exercised for common stock on September 2, 2026
Option exercise price
$21.63 per share
Exercise price of stock option converted into 58,333 common shares
Shares sold
58,333 shares
Total common shares sold in multiple open-market transactions on September 2, 2026
Sale price range (weighted averages)
$109.35–$115.44 per share
Weighted average prices across reported sale tranches
Tax withholding shares
102 shares at $113.38 per share
Shares withheld to satisfy tax obligations on RSU vesting
Purchase plan acquisition
138 shares at $113.38 per share
Shares bought under the 2024 Incentive Award Plan on September 1, 2026
Restricted stock award
138 shares
Unvested restricted shares granted September 1, 2026, vesting 100% after one year
Stock option expiration
February 1, 2034
Expiration date of the exercised stock option
Key Terms
Rule 10b5-1 plan, restricted stock awards, weighted average sale price, tax withholding obligations, +1 more
5 terms
Rule 10b5-1 plan regulatory
"This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
restricted stock awards financial
"Includes 199 shares underlying unvested restricted stock awards granted to the Reporting Person"
Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.
weighted average sale price financial
"Represents the weighted average sale price for the entire number of shares sold"
tax withholding obligations financial
"shares were withheld by the Issuer in order to satisfy certain tax withholding obligations"
Incentive Award Plan financial
"purchase plan established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan"
An incentive award plan is a formal program that rewards employees, executives, or directors with cash, stock, options, or other pay when the company meets set goals or performance targets. Like a sales commission or a loyalty program that pays out when you hit milestones, it’s designed to align staff behavior with company objectives; investors care because it affects a company’s costs, share count (dilution), leadership incentives, and long-term value creation.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Corcept Therapeutics (CORT) executive Roberto Vieira do in this Form 4?
He exercised options for 58,333 shares of Corcept common stock at $21.63 per share on September 2, 2026, then sold 58,333 shares in multiple open-market trades and had 102 shares withheld to cover tax obligations.
Were the Corcept Therapeutics (CORT) insider sales made under a Rule 10b5-1 plan?
Yes. The filing states the sales were made pursuant to a Rule 10b5-1 plan adopted by Roberto Vieira on June 17, 2026, which was in effect at the time of the September 2, 2026 transactions.
What option exercise did the Corcept Therapeutics (CORT) executive report?
He reported exercising a stock option for 58,333 shares of Corcept common stock at an exercise price of $21.63 per share. The option, expiring February 1, 2034, vests monthly after an initial 25% vesting on January 29, 2025.
AI-generated analysis. How Rhea-AI works. Not financial advice.
